March 14, 2024 01:49 PM EDTUpdated March 15, 02:55 PM
Pharma
Cell/Gene Tx

UK's NICE says it's not ready to rec­om­mend Ver­tex's Cas­gevy for sick­le cell

Katherine Lewin

News Reporter

The UK’s Na­tion­al In­sti­tute for Health and Care Ex­cel­lence isn’t quite ready to rec­om­mend Ver­tex and CRISPR Ther­a­peu­tics’ Cas­gevy for sick­le cell dis­ease, cit­ing cost …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times